about
Role of positron emission tomography for the monitoring of response to therapy in breast cancerInfluence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.18F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-DimensionIdentification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer."Staging, restaging and treatment response assessment" in lymphomas: what we should know.Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).Dual Diagnostic Role of 123I-MIBG Scintigraphy in Inverted-Takotsubo Pattern Cardiomyopathy.Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.[Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment]Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centersInterim PET in Hodgkin Lymphoma: Is It So Useless?Q95475659
P50
Q28080621-D7770457-DF5C-4403-982C-9A8263DFA7F8Q35810341-D3829CB9-6D85-447E-B413-A55C41B95A0EQ38883996-4AE9FFA9-DB99-4FE3-B3B6-BD532303ED9CQ41624801-7592F04D-7356-4613-A478-672AD06673CCQ48560457-797AE0E7-961A-4129-9E20-ABB947B7D727Q51736467-D53BA9F7-1E65-4481-A969-C5A6DA33C2ACQ51737941-424C5271-272C-44CE-ACDD-AABD098AC38BQ52590609-A5A1925E-E676-4E70-A965-1A7F1973598BQ52985576-2763BC98-764B-458F-A0F7-957E70266D78Q53001564-280EC519-82C9-4335-A212-C156EC34352EQ53078051-AD0B0BF2-67CE-473B-9141-ADED4FFC3419Q53109416-D49FE00E-D4CC-42A8-B643-C65819624F91Q55220794-58452423-677E-48E7-B17B-FCC769B376E8Q55603215-33D2F7BC-B1CD-4E0E-91C1-A52E05EB0ED5Q57126632-F4C05E72-CE27-4E9E-8DB8-F4782969C675Q89047929-F5B3BB6A-E272-4944-A779-682B9691E438Q89398549-BE17C0B1-414D-462A-B82F-617492F364DEQ95475659-35772F27-4CFA-47EB-8FCE-3F4279B4CFFA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Salim Kanoun
@ast
Salim Kanoun
@en
Salim Kanoun
@es
Salim Kanoun
@nl
Salim Kanoun
@sl
type
label
Salim Kanoun
@ast
Salim Kanoun
@en
Salim Kanoun
@es
Salim Kanoun
@nl
Salim Kanoun
@sl
prefLabel
Salim Kanoun
@ast
Salim Kanoun
@en
Salim Kanoun
@es
Salim Kanoun
@nl
Salim Kanoun
@sl
P106
P31
P496
0000-0002-8592-3773